ARCT
Arcturus Therapeutics Holdings Inc

5,503
Mkt Cap
$215.1M
Volume
570,361.00
52W High
$24.17
52W Low
$5.85
PE Ratio
-3.07
ARCT Fundamentals
Price
$7.57
Prev Close
$7.02
Open
$7.24
50D MA
$6.99
Beta
1.76
Avg. Volume
501,224.60
EPS (Annual)
-$3.00
P/B
0.92
Rev/Employee
$786,301.14
Loading...
Loading...
News
all
press releases
Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving Average - Should You Sell...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200-Day Moving Average - Here's Why
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Crosses Below 200-Day Moving Average - What's Next...
MarketBeat·2d ago
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the thirteen research firms that are covering the...
MarketBeat·10d ago
News Placeholder
Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference
Arcturus Therapeutics (NASDAQ:ARCT) CEO and President Joe Payne outlined the company's current focus on messenger RNA (mRNA) therapeutics, emphasizing a leaner operating profile and a near-term set...
MarketBeat·26d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Price Target Cut to $7.00 by Analysts at Citigroup
Citigroup cut their price objective on Arcturus Therapeutics from $9.00 to $7.00 and set a "neutral" rating for the company in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve brokerages that are currently covering the firm...
MarketBeat·1mo ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving Average - Time to Sell?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·2mo ago
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve ratings firms that are currently covering the...
MarketBeat·2mo ago
News Placeholder
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
Zacks·2mo ago
<
1
2
...
>

Latest ARCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.